Neurodegenerative process in multiple sclerosis and a possible neuroprotective effect of β-interferon 1a (avonex)

被引:0
|
作者
Davydovskaya, M. V. [1 ]
Boiko, A. N.
Podoprigora, A. E.
Pronin, I. N.
Kornienko, V. N.
Gusev, E. I.
机构
[1] Pirogov Russian Natl Res Med Univ, Moscow, Russia
关键词
multiple sclerosis; neurodegenerative process; proton magnetic-resonance spectroscopy; beta-interferon 1a for intramuscular injection; MAGNETIC-RESONANCE SPECTROSCOPY; WHITE-MATTER; DEMYELINATION; LOCALIZATION; MULTICENTER; PATHOLOGY; BRAIN;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To evaluate clinical perspectives of proton multi-voxel magnetic-resonance spectroscopy (PMMRS) for monitoring the severity of multiple sclerosis (MS) and neurodegenerative process, we studied the changes of the NAA/Cr ratio in the brain tissue of patients with MS and calculated the correlations between this parameter and the clinical state of patients. Based on these results, we studied the potential neuroprotective effect of beta-interferon 1a (avonex) for intramuscular injection in patients with remitting MS. Twenty-six patients with remitting MS were enrolled in the study. The study of anamnesis, neurological examination using EDSS, neuropsychological testing and dynamic MRI using PMMRS were performed. The NAA/Cr ratio was decreased in patients compared to controls. An analysis of the NAA/Cr ratio after one year revealed the significant decrease of this parameter. The negative correlation between the NAA/Cr ratio in the brain tissue and the level of neurological and cognitive deficits was noted. The analysis of existing treatment of MS with beta-interferon 1a for intramuscular injection revealed the neuroprotective stabilizing effect during one year of treatment that is probably associated with the effect of this drug on the neurodegenerative process in MS.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 50 条
  • [1] The neurodegenerative process in multiple sclerosis and the possible neuroprotective effect of treatment with β-interferon 1a (Avonex)
    Davydovskaya M.V.
    Boiko A.N.
    Podoprigora A.E.
    Pronin I.N.
    Kornienko V.N.
    Gusev E.I.
    [J]. Neuroscience and Behavioral Physiology, 2013, 43 (8) : 907 - 912
  • [2] The neurodegenerative process in multiple sclerosis and the possible neuroprotective effect of treatment with β-interferon 1a (avonex)
    Davydovskaya, M. V.
    Boiko, A. N.
    Podoprigora, A. E.
    Pronin, I. N.
    Kornienko, V. N.
    Gusev, E. I.
    [J]. ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (07) : 36 - 41
  • [3] Quality of life in multiple sclerosis:: influence of interferon-β1a (Avonex®) treatment
    Vermersch, P
    de Seze, J
    Delisse, B
    Lamaire, S
    Stojkovic, T
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (05) : 377 - 381
  • [4] Neuropsychological effects of Avonex® (interferon-β-1a) in relapsing multiple sclerosis (MS)
    Fischer, JS
    Priore, R
    Jacobs, L
    Cookfair, D
    Rudick, R
    Herndon, R
    Richert, J
    Salazar, A
    Goodkin, D
    Granger, C
    Simon, J
    Grafman, J
    Lezak, M
    O'Reilly, K
    Schacter, M
    Shucard, D
    Davidson, A
    Wende, K
    [J]. NEUROLOGY, 1998, 50 (04) : A32 - A33
  • [5] The effect of Avonex® (IFNβ-1a) on cerebral atrophy in relapsing multiple sclerosis
    Rudick, R
    Fisher, E
    Lee, JC
    Simon, J
    Miller, D
    Jacobs, L
    [J]. NEUROLOGY, 1999, 52 (06) : A289 - A290
  • [6] Ongoing efficacy and safety analysis of interferon-β1a (AVONEX) in patients with multiple sclerosis
    Herndon, RM
    Coats, M
    Goodkin, D
    Mass, M
    Richert, J
    Rudick, RA
    Weinstock-Guttman, B
    Simonian, NA
    Campion, M
    Scaramocci, J
    Alam, JJ
    Jacobs, LD
    [J]. ANNALS OF NEUROLOGY, 1997, 42 (06) : 987 - 987
  • [7] Interferon β1a (Avonex®) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability
    P. Vermersch
    J. de Seze
    T. Stojkovic
    P. Hautecoeur
    [J]. Journal of Neurology, 2002, 249 : 184 - 187
  • [8] Interferon β1a (Avonex®) treatment in multiple sclerosis:: similarity of effect on progression of disability in patients with mild and moderate disability
    Vermersch, R
    de Seze, J
    Stojkovic, T
    Hautecoeur, R
    [J]. JOURNAL OF NEUROLOGY, 2002, 249 (02) : 184 - 187
  • [9] Combination therapy with serotonin reuptake inhibitors and interferon β-1a (Avonex) in the treatment of multiple sclerosis:: a pilot study
    Potter, DL
    Hart, DE
    [J]. ANNALS OF NEUROLOGY, 1999, 46 (03) : 495 - 495
  • [10] Combination of IFNβ-1a (Avonex®) and mycophenolate mofetil (Cellcept®) in multiple sclerosis
    Vermersch, P.
    Waucquier, N.
    Michelin, E.
    Bourteel, H.
    Stojkovic, T.
    Ferriby, D.
    de Seze, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (01) : 85 - 89